249 related articles for article (PubMed ID: 28834425)
1. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
2. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
3. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
[TBL] [Abstract][Full Text] [Related]
4. Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.
Matrka MC; Cimperman KA; Haas SR; Guasch G; Ehrman LA; Waclaw RR; Komurov K; Lane A; Wikenheiser-Brokamp KA; Wells SI
PLoS Genet; 2018 Mar; 14(3):e1007227. PubMed ID: 29538372
[TBL] [Abstract][Full Text] [Related]
5. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.
Adams AK; Hallenbeck GE; Casper KA; Patil YJ; Wilson KM; Kimple RJ; Lambert PF; Witte DP; Xiao W; Gillison ML; Wikenheiser-Brokamp KA; Wise-Draper TM; Wells SI
Oncogene; 2015 Feb; 34(7):868-77. PubMed ID: 24608431
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Wise-Draper TM; Mintz-Cole RA; Morris TA; Simpson DS; Wikenheiser-Brokamp KA; Currier MA; Cripe TP; Grosveld GC; Wells SI
Cancer Res; 2009 Mar; 69(5):1792-9. PubMed ID: 19223548
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between DEK oncogene expression and oral squamous cell carcinoma].
Wang X; Huang SH; Yu LQ; Liu J; Diao Y; Sun CF
Shanghai Kou Qiang Yi Xue; 2014 Feb; 23(1):75-9. PubMed ID: 24608617
[TBL] [Abstract][Full Text] [Related]
8. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
9. DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.
Feng T; Liu Y; Li C; Li Z; Cai H
Tumour Biol; 2017 Jul; 39(7):1010428317716248. PubMed ID: 28670979
[TBL] [Abstract][Full Text] [Related]
10. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
11. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
12. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
[TBL] [Abstract][Full Text] [Related]
14. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
[TBL] [Abstract][Full Text] [Related]
15. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
16. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
17. p21-activated kinase 2 binds to transcription factor SOX2 and up-regulates DEK to promote the progression of lung squamous cell carcinoma.
Xie S; Wan X; Chen S; Hu Y; Liu X
Lab Invest; 2022 Oct; 102(10):1109-1120. PubMed ID: 35821094
[TBL] [Abstract][Full Text] [Related]
18. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
19. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
20. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]